A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the bioavailability of nanoparticulate OZ439
delivered to the proximal small bowel (PSB) via the Enterion™ capsule relative to oral OZ439
suspension (current "powder in bottle" [PIB]) and oral nanoparticulate OZ439.
The study will also characterise the plasma concentration time profile of OZ439 when
delivered via Enterion capsule to the PSB in comparison with OZ439 PIB formulation delivered
orally and nanoparticulate OZ439 delivered orally Safety and tolerability of OZ439
formulations will be determined following delivery to the PSB and administered orally